P-149 Impact of sequence of biologic therapies on overall survival (OS) in patients with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC): an exploratory, retrospective pooled analysis
Alberto F. Sobrero(Ospedale Policlinico San Martino), Marc Peeters(University of Antwerp), Fernando Rivera(Marqués de Valdecilla University Hospital), Frédéric Forget, Meinolf Karthaus(Evangelisches Krankenhaus Bielefeld), Gaston Demonty(Amgen (Belgium)), Jean‐Yves Douillard(Integrated Oncology (United States)), Manuel Valladares‐Ayerbes(Instituto de Biomedicina de Sevilla)
Cited by 2
Related Papers
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
|The Lancet|2008|1.2k
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2010|1k